Pleiotrophin promotes vascular abnormalization in gliomas and correlates with poor survival in patients with astrocytomas

Science Signaling

Volumn 8, Issue 406, 2015, Pages

  Zhang, Lei ^a   Kundu, Soumi ^a   Feenstra, Tjerk ^a,d   Li, Xiujuan ^a   Jin, Chuan ^a   Laaniste, Liisi ^a   El Hassan, Tamador Elsir Abu ^b   Ohlin, K Elisabet ^a   Yu, Di ^a   Olofsson, Tommie ^a   Olsson, Anna Karin ^c   Pontén, Fredrik ^a   Magnusson, Peetra U ^a   Nilsson, Karin Forsberg ^a   Essand, Magnus ^a   Smits, Anja ^b   Dieterich, Lothar C ^a,e   Dimberg, Anna ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e ETH ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CEDIRANIB; CERITINIB; CRIZOTINIB; MESSENGER RNA; PLEIOTROPHIN; VASCULOTROPIN; CARRIER PROTEIN; CYTOKINE; PROTEIN TYROSINE KINASE; TUMOR PROTEIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A, MOUSE; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

AFFECT; ANGIOGENESIS; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTOMA; CANCER CONTROL; CANCER PROGNOSIS; CANCER SURVIVAL; CAPILLARY DENSITY; CARCINOGENESIS; CELL PROLIFERATION; COMPARATIVE STUDY; CONTROLLED STUDY; EMBRYOID BODY; FEMALE; GENE EXPRESSION; GLIOMA; GLIOMA CELL LINE; HUMAN; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MEDIAN SURVIVAL TIME; MOLECULAR PATHOLOGY; MOUSE; NEUROPATHOLOGY; NONHUMAN; PERICYTE; PRIORITY JOURNAL; SPROUTING; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; ANIMAL; BRAIN TUMOR; DISEASE FREE SURVIVAL; GENETICS; MALE; METABOLISM; MORTALITY; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; SURVIVAL RATE; TUMOR CELL LINE;

ANIMALS; ASTROCYTOMA; BRAIN NEOPLASMS; CARRIER PROTEINS; CELL LINE, TUMOR; CYTOKINES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MICE; NEOPLASM PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTOR PROTEIN-TYROSINE KINASES; SURVIVAL RATE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84954317626     PISSN: 19450877     EISSN: 19379145     Source Type: Journal    
DOI: 10.1126/scisignal.aaa1690     Document Type: Article

References (56)

1. A. Omuro, L. M. DeAngelis, Glioblastoma and other malignant gliomas: A clinical review. JAMA 310, 1842-1850 (2013).
2. R. K. Jain, E. Di Tomaso, D. G. Duda, J. S. Loeffler, A. G. Sorensen, T. T. Batchelor, Angiogenesis in brain tumours. Nat. Rev. Neurosci. 8, 610-622 (2007).
3. K. H. Plate, A. Scholz, D. J. Dumont, Tumor angiogenesis and anti-angiogenic therapy in malignant gliomas revisited. Acta Neuropathol. 124, 763-775 (2012).
4. L. C. Dieterich, S. Mellberg, E. Langenkamp, L. Zhang, A. Zieba, H. Salomäki, M. Teichert, H. Huang, P.-H. Edqvist, T. Kraus, H. G. Augustin, T. Olofsson, E. Larsson, O. Söderberg, G. Molema, F. Pontén, P. Georgii-Hemming, I. Alafuzoff, A. Dimberg, Transcriptional profiling of human glioblastoma vessels indicates a key role of VEGF-A and TGFb2 in vascular abnormalization. J. Pathol. 228, 378-390 (2012).
5. H. S. Friedman, M. D. Prados, P. Y. Wen, T. Mikkelsen, D. Schiff, L. E. Abrey, W. K. A. Yung, N. Paleologos, M. K. Nicholas, R. Jensen, J. Vredenburgh, J. Huang, M. Zheng, T. Cloughesy, Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J. Clin. Oncol. 27, 4733-4740 (2009).
6. T. Muramatsu, Midkine and pleiotrophin: Two related proteins involved in development, survival, inflammation and tumorigenesis. J. Biochem. 132, 359-371 (2002).
7. K. Meng, A. Rodríguez-Peña, T. Dimitrov, W. Chen, M. Yamin, M. Noda, T. F. Deuel, Pleiotrophin signals increased tyrosine phosphorylation of b-catenin through inactivation of the intrinsic catalytic activity of the receptor-type protein tyrosine phosphatase b/z. Proc. Natl. Acad. Sci. U. S. A. 97, 2603-2608 (2000).
8. H. Pariser, G. Herradon, L. Ezquerra, P. Perez-Pinera, T. F. Deuel, Pleiotrophin regulates serine phosphorylation and the cellular distribution of b-adducin through activation of protein kinase C. Proc. Natl. Acad. Sci. U. S. A. 102, 12407-12412 (2005).
9. C. Powers, A. Aigner, G. E. Stoica, K. McDonnell, A. Wellstein, Pleiotrophin signaling through anaplastic lymphoma kinase is rate-limiting for glioblastoma growth. J. Biol. Chem. 277, 14153-14158 (2002).
10. T. F. Deuel, Anaplastic lymphoma kinase: "Ligand Independent Activation" mediated by the PTN/RPTPb/z signaling pathway. Biochim. Biophys. Acta 1834, 2219-2223 (2013).
11. K. V. Lu, K. A. Jong, G. Y. Kim, J. Singh, E. Q. Dia, K. Yoshimoto, M. Y. Wang, T. F. Cloughesy, S. F. Nelson, P. S. Mischel, Differential induction of glioblastoma migration and growth by two forms of pleiotrophin. J. Biol. Chem. 280, 26953-26964 (2005).
12. N. Zhang, R. Zhong, Z.-Y. Wang, T. F. Deuel, Human breast cancer growth inhibited in vivo by a dominant negative pleiotrophin mutant. J. Biol. Chem. 272, 16733-16736 (1997).
13. R. Jäger, K. Noll, K. Havemann, K.-H. Pflüger, C. Knabbe, H. Rauvala, G. Zugmaier, Differential expression and biological activity of the heparin-binding growth-associated molecule (HB-GAM) in lung cancer cell lines. Int. J. Cancer 73, 537-543 (1997).
14. F. Czubayko, A. M. Schulte, G. J. Berchem, A. Wellstein, Melanoma angiogenesis and metastasis modulated by ribozyme targeting of the secreted growth factor pleiotrophin. Proc. Natl. Acad. Sci. U. S. A. 93, 14753-14758 (1996).
15. A. Nakagawara, J. Milbrandt, T. Muramatsu, T. F. Deuel, H. Zhao, A. Cnaan, G. M. Brodeur, Differential expression of pleiotrophin and midkine in advanced neuroblastomas. Cancer Res. 55, 1792-1797 (1995).
16. H.-J. Klomp, O. Zernial, S. Flachmann, A. Wellstein, H. Juhl, Significance of the expression of the growth factor pleiotrophin in pancreatic cancer patients. Clin. Cancer Res. 8, 823-827 (2002).
17. W. Fang, N. Hartmann, D. T. Chow, A. T. Riegel, A. Wellstein, Pleiotrophin stimulates fibroblasts and endothelial and epithelial cells and is expressed in human cancer. J. Biol. Chem. 267, 25889-25897 (1992).
18. A. K. Chauhan, Y.-S. Li, T. F. Deuel, Pleiotrophin transforms NIH 3T3 cells and induces tumors in nude mice. Proc. Natl. Acad. Sci. U. S. A. 90, 679-682 (1993).
19. Y. Chang, M. Zuka, P. Perez-Pinera, A. Astudillo, J. Mortimer, J. R. Berenson, T. F. Deuel, Secretion of pleiotrophin stimulates breast cancer progression through remodeling of the tumor microenvironment. Proc. Natl. Acad. Sci. U. S. A. 104, 10888-10893 (2007).
20. H. Chen, R. A. Campbell, Y. Chang, M. Li, C. S. Wang, J. Li, E. Sanchez, M. Share, J. Steinberg, A. Berenson, D. Shalitin, Z. Zeng, D. Gui, P. Perez-Pinera, R. J. Berenson, J. Said, B. Bonavida, T. F. Deuel, J. R. Berenson, Pleiotrophin produced by multiple myeloma induces transdifferentiation of monocytes into vascular endothelial cells: A novel mechanism of tumor-induced vasculogenesis. Blood 113, 1992-2002 (2009).
21. F. M. Peria, L. Neder, S. K. N. Marie, S. Rosemberg, S. M. Oba-Shinjo, B. O. Colli, A. A. Gabbai, S. M. F. Malheiros, M. A. Zago, R. A. Panepucci, C. A. Moreira-Filho, O. K. Okamoto, C. G. Carlotti Jr., Pleiotrophin expression in astrocytic and oligodendroglial tumors and it's correlation with histological diagnosis, microvascular density, cellular proliferation and overall survival. J. Neurooncol. 84, 255-261 (2007).
22. S. Müller, P. Kunkel, K. Lamszus, U. Ulbricht, G. A. Lorente, A. M. Nelson, D. Von Schack, D. J. Chin, S. C. Lohr, M. Westphal, T. Melcher, A role for receptor tyrosine phosphatasez in glioma cell migration. Oncogene 22, 6661-6668 (2003).
23. U. Ulbricht, C. Eckerich, R. Fillbrandt, M. Westphal, K. Lamszus, RNA interference targeting protein tyrosine phosphatase z/receptor-type protein tyrosine phosphatase b suppresses glioblastoma growth in vitro and in vivo. J. Neurochem. 98, 1497-1506 (2006).
24. M. Grzelinski, N. Bader, F. Czubayko, A. Aigner, Ribozyme-targeting reveals the rate-limiting role of pleiotrophin in glioblastoma. Int. J. Cancer 117, 942-951 (2005).
25. M. Grzelinski, B. Urban-Klein, T. Martens, K. Lamszus, U. Bakowsky, S. Höbel, F. Czubayko, A. Aigner, RNA interference-mediated gene silencing of pleiotrophin through polyethylenimine-complexed small interfering RNAs in vivo exerts antitumoral effects in glioblastoma xenografts. Hum. Gene Ther. 17, 751-766 (2006).
26. C. Dos Santos, R. Karaky, D. Renoir, Y. Hamma-Kourbali, P. Albanese, E. Gobbo, F. Griscelli, P. Opolon, S. Dalle, M. Perricaudet, J. Courty, J. Delbé, Antitumorigenic effects of a mutant of the heparin affin regulatory peptide on the U87 MG glioblastoma cell line. Int. J. Cancer 127, 1038-1051 (2010).
27. M. Grzelinski, F. Steinberg, T. Martens, F. Czubayko, K. Lamszus, A. Aigner, Enhanced antitumorigenic effects in glioblastoma on double targeting of pleiotrophin and its receptor ALK. Neoplasia 11, 145-156 (2009).
28. L. Sooman, J. Lennartsson, J. Gullbo, M. Bergqvist, G. Tsakonas, F. Johansson, P.-H. Edqvist, F. Pontén, A. Jaiswal, S. Navani, I. Alafuzoff, S. Popova, E. Blomquist, S. Ekman, Vandetanib combined with a p38 MAPK inhibitor synergistically reduces glioblastoma cell survival. Med. Oncol. 30, 638 (2013).
29. S. N. Popova, M. Bergqvist, A. Dimberg, P.-H. Edqvist, S. Ekman, G. Hesselager, F. Ponten, A. Smits, L. Sooman, I. Alafuzoff, Subtyping of gliomas of various WHO grades by the application of immunohistochemistry. Histopathology 64, 365-379 (2014).
30. L. A. M. Gravendeel, M. C. M. Kouwenhoven, O. Gevaert, J. J. De Rooi, A. P. Stubbs, J. E. Duijm, A. Daemen, F. E. Bleeker, L. B. C. Bralten, N. K. Kloosterhof, B. De Moor, P. H. C. Eilers, P. J. Van Der Spek, J. M. Kros, P. A. E. Sillevis Smitt, M. J. Van Den Bent, P. J. French, Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology. Cancer Res. 69, 9065-9072 (2009).
31. S. Madhavan, J.-C. Zenklusen, Y. Kotliarov, H. Sahni, H. A. Fine, K. Buetow, Rembrandt: Helping personalized medicine become a reality through integrative translational research. Mol. Cancer Res. 7, 157-167 (2009).
32. B. Wiestler, D. Capper, T. Holland-Letz, A. Korshunov, A. Von Deimling, S. M. Pfister, M. Platten, M. Weller, W. Wick, ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis. Acta Neuropathol. 126, 443-451 (2013).
33. H. Yan, D. W. Parsons, G. Jin, R. McLendon, B. A. Rasheed, W. Yuan, I. Kos, I. Batinic-Haberle, S. Jones, G. J. Riggins, H. Friedman, A. Friedman, D. Reardon, J. Herndon, K. W. Kinzler, V. E. Velculescu, B. Vogelstein, D. D. Bigner, IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 360, 765-773 (2009).
34. H. Noushmehr, D. J. Weisenberger, K. Diefes, H. S. Phillips, K. Pujara, B. P. Berman, F. Pan, C. E. Pelloski, E. P. Sulman, K. P. Bhat, R. G. W. Verhaak, K. A. Hoadley, D. N. Hayes, C. M. Perou, H. K. Schmidt, L. Ding, R. K. Wilson, D. Van Den Berg, H. Shen, H. Bengtsson, P. Neuvial, L. M. Cope, J. Buckley, J. G. Herman, S. B. Baylin, P. W. Laird, K. Aldape; Cancer Genome Atlas Research Network, Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17, 510-522 (2010).
35. T. Szatmári, K. Lumniczky, S. Désaknai, S. Trajcevski, E. J. Hídvégi, H. Hamada, G. Sáfrány, Detailed characterization of the mouse glioma 261 tumor model for experimental glioblastoma therapy. Cancer Sci. 97, 546-553 (2006).
36. E. Wassberg, F. Hedborg, E. Sköldenberg, M. Stridsberg, R. Christofferson, Inhibition of angiogenesis induces chromaffin differentiation and apoptosis in neuroblastoma. Am. J. Pathol. 154, 395-403 (1999).
37. E. Dejean, M. H. Renalier, M. Foisseau, X. Agirre, N. Joseph, G. R. De Paiva, T. Al Saati, J. Soulier, C. Desjobert, L. Lamant, F. Prósper, D. W. Felsher, J. Cavaillé, H. Prats, G. Delsol, S. Giuriato, F. Meggetto, Hypoxia-microRNA-16 downregulation induces VEGF expression in anaplastic lymphoma kinase (ALK)-positive anaplastic large-cell lymphomas. Leukemia 25, 1882-1890 (2011).
38. J. I. Greenberg, D. J. Shields, S. G. Barillas, L. M. Acevedo, E. Murphy, J. Huang, L. Scheppke, C. Stockmann, R. S. Johnson, N. Angle, D. A. Cheresh, A role for VEGF as a negative regulator of pericyte function and vessel maturation. Nature 456, 809-813 (2008).
39. S. Koch, L. A. Van Meeteren, E. Morin, C. Testini, S. Weström, H. Björkelund, S. Le Jan, J. Adler, P. Berger, L. Claesson-Welsh, NRP1 presented in trans to the endothelium arrests VEGFR2 endocytosis, preventing angiogenic signaling and tumor initiation. Dev. Cell 28, 633-646 (2014).
40. T. Inai, M. Mancuso, H. Hashizume, F. Baffert, A. Haskell, P. Baluk, D. D. Hu-Lowe, D. R. Shalinsky, G. Thurston, G. D. Yancopoulos, D. M. McDonald, Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am. J. Pathol. 165, 35-52 (2004).
41. A. Armulik, G. Genové, M. Mäe, M. H. Nisancioglu, E. Wallgard, C. Niaudet, L. He, J. Norlin, P. Lindblom, K. Strittmatter, B. R. Johansson, C. Betsholtz, Pericytes regulate the blood-brain barrier. Nature 468, 557-561 (2010).
42. E. D. Foehr, G. Lorente, J. Kuo, R. Ram, K. Nikolich, R. Urfer, Targeting of the receptor protein tyrosine phosphatase b with a monoclonal antibody delays tumor growth in a glioblastoma model. Cancer Res. 66, 2271-2278 (2006).
43. D. C. Stylianou, A. Auf Der Maur, D. P. Kodack, R. T. Henke, S. Hohn, J. A. Toretsky, A. T. Riegel, A. Wellstein, Effect of single-chain antibody targeting of the ligand-binding domain in the anaplastic lymphoma kinase receptor. Oncogene 28, 3296-3306 (2009).
44. R. Choudhuri, H.-T. Zhang, S. Donnini, M. Ziche, R. Bicknell, An angiogenic role for the neurokines midkine and pleiotrophin in tumorigenesis. Cancer Res. 57, 1814-1819 (1997).
45. A. M. Schulte, S. Lai, A. Kurtz, F. Czubayko, Anna T. Riegel, A. Wellstein, Human trophoblast and choriocarcinoma expression of the growth factor pleiotrophin attributable to germ-line insertion of an endogenous retrovirus. Proc. Natl. Acad. Sci. U. S. A. 93, 14759-14764 (1996).
46. L. Calvet, B. Geoerger, M. Regairaz, P. Opolon, L. Machet, J. Morizet, J.-M. Joseph, N. Elie, G. Vassal, Pleiotrophin, a candidate gene for poor tumor vasculature and in vivo neuroblastoma sensitivity to irinotecan. Oncogene 25, 3150-3159 (2006).
47. A. Parthymou, E. Lampropoulou, C. Mikelis, G. Drosou, E. Papadimitriou, Heparin affin regulatory peptide/pleiotrophin negatively affects diverse biological activities in C6 glioma cells. Eur. J. Cell Biol. 87, 17-29 (2008).
48. 3 is a pleiotrophin receptor required for pleiotrophin-induced endothelial cell migration through receptor protein tyrosine phosphatase b/z. FASEB J. 23, 1459-1469 (2009).
49. Y. Kong, P. Bai, K. Nan, H. Sun, N. Chen, X. Qi, Pleiotrophin is a potential colorectal cancer prognostic factor that promotes VEGF expression and induces angiogenesis in colorectal cancer. Int. J. Colorectal Dis. 27, 287-298 (2012).
50. B. Hallberg, R. H. Palmer, Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology. Nat. Rev. Cancer 13, 685-700 (2013).
51. Cancer Genome Atlas Research Network, Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N. Engl. J. Med. 372, 2481-2498 (2015).
52. C. W. Brennan, R. G. W. Verhaak, A. McKenna, B. Campos, H. Noushmehr, S. R. Salama, S. Zheng, D. Chakravarty, J. Z. Sanborn, S. H. Berman, R. Beroukhim, B. Bernard, C.-J. Wu, G. Genovese, I. Shmulevich, J. Barnholtz-Sloan, L. Zou, R. Vegesna, S. A. Shukla, G. Ciriello, W. K. Yung, W. Zhang, C. Sougnez, T. Mikkelsen, K. Aldape, D. D. Bigner, E. G. Van Meir, M. Prados, A. Sloan, K. L. Black, J. Eschbacher, G. Finocchiaro, W. Friedman, D. W. Andrews, A. Guha, M. Iacocca, B. P. O'Neill, G. Foltz, J. Myers, D. J. Weisenberger, R. Penny, R. Kucherlapati, C. M. Perou, D. N. Hayes, R. Gibbs, M. Marra, G. B. Mills, E. Lander, P. Spellman, R. Wilson, C. Sander, J. Weinstein, M. Meyerson, S. Gabriel, P. W. Laird, D. Haussler, G. Getz, L. Chin; TCGA Research Network, The somatic genomic landscape of glioblastoma. Cell 155, 462-477 (2013).
53. T. Matsumoto, P. Schiller, L. C. Dieterich, F. Bahram, Y. Iribe, U. Hellman, C. Wikner, G. Chan, L. Claesson-Welsh, A. Dimberg, Ninein is expressed in the cytoplasm of angiogenic tip-cells and regulates tubular morphogenesis of endothelial cells. Arterioscler. Thromb. Vasc. Biol. 28, 2123-2130 (2008).
54. C. Rolny, I. Nilsson, P. Magnusson, A. Armulik, L. Jakobsson, P. Wentzel, P. Lindblom, J. Norlin, C. Betsholtz, R. Heuchel, M. Welsh, L. Claesson-Welsh, Platelet-derived growth factor receptor-b promotes early endothelial cell differentiation. Blood 108, 1877-1886 (2006).
55. A. El Andaloussi, A. M. Sonabend, Y. Han, M. S. Lesniak, Stimulation of TLR9 with CpG ODN enhances apoptosis of glioma and prolongs the survival of mice with experimental brain tumors. Glia 54, 526-535 (2006).
56. H. Kawamura, X. Li, K. Goishi, L. A. Van Meeteren, L. Jakobsson, S. Cébe-Suarez, A. Shimizu, D. Edholm, K. Ballmer-Hofer, L. Kjellén, M. Klagsbrun, L. Claesson-Welsh, Neuropilin-1 in regulation of VEGF-induced activation of p38MAPK and endothelial cell organization. Blood 112, 3638-3649 (2008).